BCL2 and non-Hodgkin lymphoma: TQB3909: In China, the Chia Tai Tianqing Pharmaceutical Group (www.cttq.com) are the sponsors of several phase I trials evaluating the efficacy of the BCL2 inhibitor, TQB3909, in patients with R/R NHL, AML, MCL, plasmacytoma, myelofibrosis, MDS or HR-positive and HER2 negative advanced or metastatic breast cancer.